Vistagen to participate at william blair biotech focus conference 2022

South san francisco, calif.--(business wire)---- $vtgn #ph94b--vistagen therapeutics, inc. (nasdaq: vtgn) (vistagen), a late clinical-stage, central nervous system (cns)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other cns disorders, today announced that chief executive officer shawn singh will participate in a panel discussing unmet needs and novel therapies in neuropsychiatry at the william blair biotech focus conference on
VTGN Ratings Summary
VTGN Quant Ranking